Measuring chemotherapy-induced peripheral neuropathy in children: Development of the Ped-mTNS and pilot study results

Rehabilitation Oncology

Volumn 27, Issue 3, 2009, Pages 7-15

  Gilchrist, Laura S ^a,b   Tanner, Lynn ^b   Hooke, Mary C ^b  

^a ST CATHERINE UNIVERSITY   (United States)

^b Children's Hospitals and Clinics of MN

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL EXAMINATION; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; MUSCLE STRENGTH; PERIPHERAL NEUROPATHY; PHYSICAL DISEASE BY BODY FUNCTION; PILOT STUDY; PRESCHOOL CHILD; SCHOOL CHILD; SENSIBILITY; SENSORY DYSFUNCTION; SYMPTOM; TENDON REFLEX; VIBRATION;

EID: 77953368803     PISSN: 21683808     EISSN: 23812427     Source Type: Journal    
DOI: 10.1097/01893697-200927030-00002     Document Type: Article

References (26)

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2005 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009. Available at: www.cdc.gov/uscs. Accessed September 3, 2009
2. Verstappen CCP, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications in patients with cancer: clinical signs and optimal management. Drugs. 2003;63:1549-1563. (Pubitemid 36976138)
3. Markman M. Chemotherapy-induced peripheral neuropathy: underreported and underappreciated. Curr Pain Headache Rep. 2006;10:275-278. (Pubitemid 44122750)
4. Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Onc Nurs Forum. 2005;32:305-311.
5. Lavoie Smith EM, Beck SL, Cohen J. The Total Neuropathy Scale: A tools for measuring chemotherapy-related peripheral neuropathy. Oncol Nurs Forum. 2008;35:96-102.
6. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR. Dysfunction of multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with vincristine-induced pain. J Pain Symptom Manage. 2007;33:166-179. (Pubitemid 46186866)
7. Meijer C, de Vries EG, Marmiroli P, Tredici G, Frattola L, Cavaletti G. Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology. 1999;20:883-887. (Pubitemid 30091215)
8. Wright MJ, Galea V, Barr RD. Proficiency of balance in children and youth who have had acute lymphoblastic leukemia. Phys Ther. 2005;85(8):782-790. (Pubitemid 41060369)
9. Hartman A, van den Bos C, Stijnen T, Pieters R. Decreased motor performance in children with cancer is independent of the cumulative dose of vincristine. Cancer. 2006;106:1395-1401. (Pubitemid 43363920)
10. Florin TA, Fryer GE, Miyoshi T, et al. Physical inactivity in adult survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2007;16:1356-1363. (Pubitemid 47076864)
11. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Cl J Oncol Nurs. 2007;11:901-913.
12. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, published August 9, 2006. Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed June 23, 2008.
13. Cornblath DR, Chaudhry V, Carter MS, et al. Total Neuropathy Scale: validation and reliability study. Neurol. 1999;53:1660-1664. (Pubitemid 29530336)
14. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurol. 2003;61:1297-1300. (Pubitemid 37377562)
15. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Scale for chemotherapy-induced peripheral neurotoxicity. J Periph Nerv Syst. 2006;11:135-141. (Pubitemid 43894080)
16. Wampler MA, Miaskowski C, Hamel K, Byl N, Rugo H, Topp KS. The modified total neuropathy score: a clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. J Support Oncol. 2006;4:9-16.
17. Wampler MA, Topp KS, Miaskowski C, Byl NN, Rugo HS, Hamel K. Quantitative and clinical description of postural instability in women with breast cancer treated with taxane chemotherapy. Arch Phys Med Rehabil. 2007;88:1002-1008. (Pubitemid 47126397)
18. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Scale as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007;12:210-215. (Pubitemid 47404378)
19. Friedrichsdorf SJ, Finney D, Bergin M, Stevens M, Collins JJ. Breakthrough pain in children with cancer. J Pain Sympt Manag. 2007;34:209-216.
20. Hilz MJ, Axelrod FB, Hermann K, Haertl U, Duetsch M, Neundörfer B. Normative values of vibratory perception in 530 children, juveniles, and adults aged 3-79 years. J Neurolog Sci. 1998;159:219-225. (Pubitemid 28384533)
21. Coutinho dos Santos LH, Bruck I, Antoniuk SA, Sandrini R. Evaluation of sensorimotor polyneuropathy in children and adolescents with type I diabetes: association with microalbuminuria and retinopathy. Pediatric Diabetes. 2002;3:101-108.
22. Medical Research Council of the United Kingdom. Aids to Examination of the Peripheral Nervous System: Memorandum No 45. Palo Alto, CA: Pedragon House; 1978.
23. Dick JPR. The deep tendon and the abdominal reflexes. J Neurol Neurosurg Psychaitry. 2003;74:150-153.
24. Owczarek J, Jasińska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep. 2005;57:23-34.
25. Lefaucheur J-P, Créange A, Neurophysiological testing correlates with clinical examination according to fiber type involvement and severity in sensory neuropathy. J Neurol Neurosurg Psychiatry. 2004;75:417-422. (Pubitemid 38338772)
26. th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.